RGLS_OUT_1 [2025-03-27 11:16:03 -0400] 2215 Bytes | 633 tokens | Cum: 633 tkns (7.91% of 8k)
==========================================================================

We're scouting for winners today. Its 11:16:01 AM on Thu Mar 27, 2025 -0400 and I'm looking at Regulus Therapeutics (RGLS) up to 1.58 from 1.29

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for Regulus Therapeutics:

C1 - Today 07:00AM - Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
C2 - Mar-19-25 12:00PM - What Makes Regulus (RGLS) a New Buy Stock
C3 - Mar-18-25 04:44AM - Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now
C4 - Mar-13-25 04:18PM - Regulus: Q4 Earnings Snapshot
C5 - Mar-13-25 04:18PM 04:05PM - Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
C6 - Mar-04-25 08:00AM - Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
C7 - Feb-21-25 03:42AM - Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently
C8 - Feb-04-25 08:00AM - Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Prior AI Reports for RGLS:

1. 2025-03-27 – Score: – – Target: – – Highs: – / – / –

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Regulus Therapeutics (RGLS)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

RGLS_OUT_3 [2025-03-27 11:16:11 -0400] 1102 Bytes | 314 tokens | Cum: 949 tkns (11.86% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)**
Date: Today 07:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-successful-completion-of-its-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-farabursen-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-302412705.html

Positive Topline Data from the Fourth Cohort of Patients

Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure

Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months

Exploratory analysis of patients from hi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RGLS_OUT_5 [2025-03-27 11:16:13 -0400] 948 Bytes | 285 tokens | Cum: 1370 tkns (17.12% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T12:05:52Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Anebulo Pharmaceuticals (NASDAQ:ANEB...
A2 - 2025-03-27T12:28:08Z - Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Fa...
A3 - 2025-03-27T11:01:33Z - Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) C...
A4 - 2025-03-20T12:36:44Z - 4 best stocks to buy under $5...
A5 - 2025-03-18T15:42:43Z - Regulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at Canaccord Genuity Group...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RGLS_OUT_7 [2025-03-27 11:16:15 -0400] 1098 Bytes | 338 tokens | Cum: 1710 tkns (21.38% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Anebulo Pharmaceuticals (NASDAQ:ANEB), Edap TMS (NASDAQ:EDAP)**Date: 2025-03-27Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44512164/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers Soleno Therapeutics SLNO shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. Ocean Biomedical OCEA shares moved upwards by 23.05% to $0.1. The market value of their outstanding shares is at $14.4 million. Edap TMS EDAP shares increased by 20.48% to $2.47. The market value of their outstanding shares is at $91.6 million. As per the press release, Q4 earnings came out today. XTL Biopharmaceuticals XTLB shares moved upwards by 16.36% to $1.28. The company's market cap stands at

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RGLS_OUT_9 [2025-03-27 11:16:16 -0400] 873 Bytes | 292 tokens | Cum: 2004 tkns (25.05% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-25T11:27:06Z - Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
B2 - 2024-03-14T17:38:41Z - Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B3 - 2024-03-14T16:07:00Z - Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
B4 - 2024-03-13T16:09:00Z - Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
B5 - 2024-03-13T10:18:00Z - How Communities Impact Penny Stocks, 3 Ways
B6 - 2024-03-12T18:57:39Z - Gold Down Over 1%; ClearOne Shares Spike Higher

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RGLS_OUT_11 [2025-03-27 11:16:24 -0400] 1098 Bytes | 304 tokens | Cum: 2310 tkns (28.88% of 8k)
==========================================================================

Showing B1 (chunk 1 of 2): B1:
**Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/06/39474887/ball-to-rally-more-than-23-here-are-10-top-analyst-forecasts-for-tuesdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

JP Morgan cut the price target for Sea Limited (NYSE:SE) from $84 to $78. JP Morgan analyst Ranjan Sharma downgraded the stock from Overweight to Neutral. Sea shares gained 0.6% to close at $75.89 on Monday. See how other analysts view this stock.
Morgan Stanley raised the price target for Birkenstock Holding plc (NYSE:BIRK) from $44 to $58. Morgan Stanley analyst Edouard Aubin maintained an Equal-Weight rating. Birkenstock shares fell 2.8% to close at $59.78 o

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RGLS_OUT_13 [2025-03-27 11:16:30 -0400] 457 Bytes | 133 tokens | Cum: 2568 tkns (32.10% of 8k)
==========================================================================

Showing B1 (chunk 2 of 2): n Monday. See how other analysts view this stock.
TD Cowen boosted Credo Technology Group Holding Ltd (NASDAQ:CRDO) price target from $24 to $35. TD Cowen analyst Matt Ramsay upgraded the stock from Hold to Buy. Credo ...Full story available on Benzinga.com

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RGLS_OUT_15 [2025-03-27 11:16:32 -0400] 1117 Bytes | 282 tokens | Cum: 2947 tkns (36.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 8-K Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (R...

S2 - 2025-03-13 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis and our financial statements and related notes included elsewhere in this Annual Report. The following discussion contains forwar...

S3 - 2025-03-13 8-K Item2.02 Results of Oper and Fin Cond.

On March 13, 2025, we issued a press release announcing our financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RGLS_OUT_17 [2025-03-27 11:16:40 -0400] 1068 Bytes | 275 tokens | Cum: 3224 tkns (40.30% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item7.01 Regulation FD Disclosure.

Furnished as Exhibit 99.1 to this report is a presentation of Regulus Therapeutics Inc. (the Company), relating to topline results from the fourth cohort of patients in the Companys Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RGLS_OUT_19 [2025-03-27 11:16:50 -0400] 5694 Bytes | 1629 tokens | Cum: 4979 tkns (62.24% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| Volume: 9,120,843 | SMA50: 22.42% | Market Cap: 103.96M | Option/Short: Yes / Yes | Sales past 5Y: -10.71% | Sales Surprise: - |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| Avg Volume: 476.23K | SMA200: 0.61% | Shs Outstand: 65.50M | Short Float: 3.83% | Employees: 34 | EPS Surprise: 4.76% |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| Rel Volume: 71.14 | Perf Week: 15.40% | Shs Float: 53.18M | Short Ratio: 4.28 | Debt/Eq: 0.01 | P/E: - |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| RSI (14): 61.13 | Perf Month: 15.40% | Inst Own: 63.69% | Short Interest: 2.04M | Sales Y/Y TTM: - | Earnings: Mar 13 AMC |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| ATR (14): 0.13 | Perf Quarter: 2.58% | Insider Own: 19.71% | Beta: 1.21 | ROE: -95.00% | |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+
| SMA20: 14.35% | Index: RUT | Insider Trans: -1.33% | Sales Q/Q: - | ROI: -60.45% | |
+---------------------+---------------------+-----------------------+-------------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Regulus Therapeutics Inc. (RGLS) by CALSADA CRISPINA (Chief Financial Officer) on 2025-01-30
- Stock Option (Right to Buy): 562500 shares at $0 (D)

Inside Trans: Regulus Therapeutics Inc. (RGLS) by Aker Christopher Ray (Sr. VP & General Counsel) on 2025-01-30
- Stock Option (Right to Buy): 487500 shares at $0 (D)

Inside Trans: Regulus Therapeutics Inc. (RGLS) by BALTIMORE DAVID (Unknown Title) on 2025-01-30
- Common Stock: 19610 shares at $1.06 (D)

Inside Trans: Regulus Therapeutics Inc. (RGLS) by Klassen Preston (President & Head of R & D) on 2025-01-30
- Stock Option (Right to Buy): 675000 shares at $0 (D)

Inside Trans: Regulus Therapeutics Inc. (RGLS) by Hagan Joseph P (Chief Executive Officer) on 2025-01-30
- Common Stock: 50000 shares at $1.0852 (D)
- Stock Option (Right to Buy): 1350000 shares at $0 (D)

Inside Trans: Regulus Therapeutics Inc. (RGLS) by Klassen Preston (President & Head of R & D) on 2025-01-13
- Common Stock: 31445 shares at $1.2632 (D) Footnote: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 9, 2025. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -46358000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.5607
Average Volume: 677582.43
30-Day High: 1.5607
30-Day Low: 1.26

[Detailed Financials: TTM 2024]
- Total Assets: $84,181,000.0
- Total Liabilities: $7,773,000.0
- Total Equity: $76,408,000.0
- Current Assets: $82,345,000.0
- Current Liabilities: $7,499,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.82

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $14,761,000.0

[Detailed Financials: FY 2024]
- Total Assets: $84,181,000.0
- Total Liabilities: $7,773,000.0
- Total Equity: $76,408,000.0
- Current Assets: $82,345,000.0
- Current Liabilities: $7,499,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.82

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $14,761,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

RGLS_OUT_21 [2025-03-27 11:16:53 -0400] 676 Bytes | 167 tokens | Cum: 5344 tkns (66.80% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

RGLS_IN_23 [2025-03-27 11:16:54 -0400] 126 Bytes | 29 tokens | Cum: 5401 tkns (67.51% of 8k)
==========================================================================

====================================
[2025-03-27 08:16:54] # Analysis Completed
Elapsed Time: 52.87 seconds